Chugai Pharmaceutical Co Ltd
TSE:4519
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4 684
7 855
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Chugai Pharmaceutical Co Ltd
Chugai Pharmaceutical Co Ltd
Cost of Revenue
Chugai Pharmaceutical Co Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Cost of Revenue
-¥337.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-5%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Cost of Revenue
-¥1.5T
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-12%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Cost of Revenue
-¥420B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-6%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Cost of Revenue
-¥648.6B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-4%
|
|
|
S
|
Shionogi & Co Ltd
TSE:4507
|
Cost of Revenue
-¥59.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
3%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Cost of Revenue
-¥383.6B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
|
Chugai Pharmaceutical Co Ltd
Glance View
Chugai Pharmaceutical Co., Ltd., founded in 1925 and headquartered in Tokyo, Japan, is a leading biopharmaceutical company renowned for its innovative research and development in the fields of oncology, immunology, and neuroscience. As a subsidiary of the Swiss multinational Roche, Chugai stands out not just in Japan but globally, leveraging its strong heritage in drug discovery and therapeutic development. The company prides itself on its robust pipeline of proprietary drugs, highlighting its commitment to addressing unmet medical needs. With a focus on precision medicine, Chugai has made significant strides in advancing targeted therapies, marking its stature as a key player in the rapidly evolving biopharmaceutical landscape. For investors, Chugai presents a compelling opportunity, underpinned by a solid financial foundation, continued investment in R&D, and strategic partnerships that amplify its market position. The company has consistently reported strong revenue growth driven by successful product launches and an expanding range of biosimilars alongside its patented medications. With its shares being publicly traded on the Tokyo Stock Exchange, investors have an opportunity to tap into Chugai’s promising future, particularly as the global demand for advanced therapeutics escalates. As healthcare continues to evolve, Chugai's focus on advancing innovative solutions positions it well for sustained growth and profitability, making it a worthwhile consideration for those looking to invest in the biopharmaceutical sector.
See Also
What is Chugai Pharmaceutical Co Ltd's Cost of Revenue?
Cost of Revenue
-337.2B
JPY
Based on the financial report for Sep 30, 2024, Chugai Pharmaceutical Co Ltd's Cost of Revenue amounts to -337.2B JPY.
What is Chugai Pharmaceutical Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-5%
Over the last year, the Cost of Revenue growth was 37%. The average annual Cost of Revenue growth rates for Chugai Pharmaceutical Co Ltd have been -4% over the past three years , -5% over the past five years , and -5% over the past ten years .
You don't have any saved screeners yet
